ArticleTranslational cancer research2026
Adaptive radiotherapy based on nodal response to induction chemotherapy in nasopharyngeal carcinoma: a retrospective dose de-escalation analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Induction chemotherapy (IC) substantially reduces tumor burden in locoregionally advanced nasopharyngeal carcinoma (LA-NPC), enabling radiotherapy target volume optimization based on post-IC tumor volume. However, most existing studies have focused on the primary tumor, with limited attention to cervical nodal targets. This study aimed to evaluate the long-term efficacy and safety of response-adapted nodal dose de-escalation in patients achieving complete nodal response after IC without high-risk features. Methods: A retrospective analysis was conducted on 214 patients with stage II-IVA NPC treated with IC followed by intensity-modulated radiotherapy (IMRT) between June 2018 and December 2020. Patients with complete nodal response post-IC and no high-risk features-defined as necrosis, extranodal extension, nodal size ≥3 cm, or multiple nodes within a single drainage level-were selected for dose de-escalation (50-64 Gy) to the nodal gross tumor volume (GTVnd) and the corresponding clinical target volume (CTV). Treatment outcomes, Epstein-Barr virus (EBV) DNA kinetics, dosimetric parameters, and toxicities were systematically analyzed. Results: The complete nodal response rate post-IC was 33.6% (72/214). A total of 60 patients (28.0%) who achieved complete response without high-risk features met the criteria for nodal dose de-escalation. After a median follow-up of 45.0 months, no nodal recurrences were observed within de-escalated regions. The 3-year progression-free survival (PFS), overall survival (OS), and locoregional relapse-free survival (LRRFS) rates were 91.7%, 96.7%, and 100%, respectively. Dose de-escalation significantly reduced radiation exposure to salivary glands and was associated with a low incidence of late xerostomia.Patients with complete response demonstrated significantly higher EBV DNA clearance rates post-IC (80.6% Conclusions: For LA-NPC patients achieving nodal complete response after IC and without high-risk features, tailored dose reduction to nodal GTV and CTV achieved excellent locoregional control with reduced long-term toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.